Mostrar el registro sencillo del ítem
Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology
dc.contributor.author | Gomez Rial, Jose | |
dc.contributor.author | Currás Tuala, María José | |
dc.contributor.author | Rivero Calle, Irene | |
dc.contributor.author | Gómez Carballa, Alberto | |
dc.contributor.author | Cebey López, Miriam | |
dc.contributor.author | Rodríguez-Tenreiro Sánchez, Carmen | |
dc.contributor.author | DACOSTA URBIETA, ANA ISABEL | |
dc.contributor.author | RIVERO VELASCO, CARMEN | |
dc.contributor.author | Rodríguez Núñez, Nuria | |
dc.contributor.author | TRASTOY PENA, ROCIO | |
dc.contributor.author | Rodríguez García, Javier | |
dc.contributor.author | Salas Ellacuriaga, Antonio | |
dc.contributor.author | Martinón Torres, Federico | |
dc.date.accessioned | 2022-04-26T07:42:39Z | |
dc.date.available | 2022-04-26T07:42:39Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1664-3224 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/33072099 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16513 | |
dc.description.abstract | Background: Emerging evidence indicates a potential role for monocytes in COVID-19 immunopathology. We investigated two soluble markers of monocyte activation, sCD14 and sCD163, in COVID-19 patients, with the aim of characterizing their potential role in monocyte-macrophage disease immunopathology. To the best of our knowledge, this is the first study of its kind. Methods: Fifty-nine SARS-Cov-2 positive hospitalized patients, classified according to ICU or non-ICU admission requirement, were prospectively recruited and analyzed by ELISA for levels of sCD14 and sCD163, along with other laboratory parameters, and compared to a healthy control group. Results: sCD14 and sCD163 levels were significantly higher among COVID-19 patients, independently of ICU admission requirement, compared to the control group. We found a significant correlation between sCD14 levels and other inflammatory markers, particularly Interleukin-6, in the non-ICU patients group. sCD163 showed a moderate positive correlation with the time lapsed from admission to sampling, independently of severity group. Treatment with corticoids showed an interference with sCD14 levels, whereas hydroxychloroquine and tocilizumab did not. Conclusions: Monocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission. These data suggest a preponderant role for monocyte-macrophage activation in the development of immunopathology of COVID-19 patients. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.mesh | Macrophage Activation | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Macrophages | * |
dc.subject.mesh | Adrenal Cortex Hormones | * |
dc.subject.mesh | Interleukin-6 | * |
dc.subject.mesh | Monocytes | * |
dc.subject.mesh | Patient Admission | * |
dc.subject.mesh | Antibodies | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Time Factors | * |
dc.subject.mesh | Hydroxychloroquine | * |
dc.subject.mesh | Intensive Care Units | * |
dc.subject.mesh | Aged | * |
dc.title | Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology | en |
dc.type | Journal Article | es |
dc.authorsophos | Gómez-Rial, J.;Currás-Tuala, M. J.;Rivero-Calle, I.;Gómez-Carballa, A.;Cebey-López, M.;Rodríguez-Tenreiro, C.;Dacosta-Urbieta, A.;Rivero-Velasco, C.;Rodríguez-Núñez, N.;Trastoy-Pena, R.;Rodríguez-García, J.;Salas, A.;Martinón-Torres, F. | |
dc.identifier.doi | 10.3389/fimmu.2020.560381 | |
dc.identifier.pmid | 33072099 | |
dc.identifier.sophos | 39101 | |
dc.journal.title | Frontiers in Immunology | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Análise clínicos | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Medicina intensiva | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Microbioloxía | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Neumoloxía | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Pediatría | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | es |
dc.page.initial | 560381 | es |
dc.rights.accessRights | openAccess | |
dc.subject.decs | interleucina-6 | * |
dc.subject.decs | admisión de pacientes | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | hormonas de la corteza suprarrenal | * |
dc.subject.decs | anticuerpos | * |
dc.subject.decs | adulto | * |
dc.subject.decs | anciano | * |
dc.subject.decs | monocitos | * |
dc.subject.decs | humanos | * |
dc.subject.decs | factores de tiempo | * |
dc.subject.decs | unidades de cuidados intensivos | * |
dc.subject.decs | hidroxicloroquina | * |
dc.subject.decs | macrófagos | * |
dc.subject.decs | activación de macrófagos | * |
dc.subject.keyword | CHUS | es |
dc.subject.keyword | IDIS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 11 | es |